For example, in a study investigating the impact of global and gene-specific DNA methylation status (promoters of 5 stem cell-related transcription factor genes SOX2, OCT4, KLF4, MYC, and NANO) in AML patients treated with decitabine [65], Zhang et al. showed that patients with a high level of 5-mC had a poor prognosis after demethylation therapy, and higher methylation status of the SOX2 and OCT4 genes was associated with differential response to demethylation therapy. This evidence concerns the gene POU5F1 and acute myeloid leukemia.